California, USA- RapidAI, a global leader in developing Artificial Intelligence (AI) solutions for life-threatening neurovascular, trauma, cardiac, and vascular conditions, has earned a spot in CB Insights’ highly regarded Digital Health 50 list for 2023. This annual list recognizes companies making significant contributions to the healthcare sector.
This recognition comes amid ongoing success for RapidAI, including the recent launch of its Edge Cloud Platform, Shonin clearance, international expansion into Japan – the second-largest stroke market globally – and FDA clearance of Rapid SDH. These achievements follow a $75 million Series C funding round earlier this year, displaying continued momentum and commitment to innovation.
Moreover, Distinguished as the sole platform supporting deep clinical AI, RapidAI is reshaping treatment planning by enhancing medical images with additional context. This includes localization, quantification, characterization, visualization, and tracking of potentially serious conditions. This capability empowers physicians in hospitals of all sizes and locations to make quicker, more precise diagnostic and treatment decisions.
“Hospitals and care teams around the globe are looking for ways to get more out of their imaging and AI solutions, and this acknowledgement validates the key role RapidAI is playing in making providers more efficient, relieving burnout, increasing equity of access to advanced imaging technology, and improving care for all patients,” said Karim Karti, CEO of RapidAI. “We’re honored to be recognized for our contributions by providing an unmatched level of clinical depth across multiple disease states.”
Also Read: Transforming Healthcare in the Middle East: Welcoming the Digital Future
Furthermore, CB Insights meticulously selected the 2023 Digital Health 50 honorees from over 10,000 companies, recognizing excellence in the digital health landscape. They specifically acknowledged RapidAI in the Diagnosis and Imaging category, highlighting its dedication to early detection and diagnosis through contemporary technologies.
